Navigation Links
Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
Date:1/6/2011

;The financial terms of Montaur's funding commitment are substantially similar to those of the private placement of common stock with regards to the per share purchase price, warrant coverage and terms of the warrants issued to each purchaser.

"The completion of this financing is a watershed event for the Company as we believe that we now have sufficient funds to substantially complete the product development, clinical studies and manufacturing of both our Prelude SkinPrep System, our skin permeation platform technology, and our Symphony tCGM System, our needle-free continuous glucose monitoring system," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are now fully prepared to support the near-term commercialization of Prelude for the topical delivery of 4% lidocaine cream through our partner, Ferndale Pharma Group.  Additionally, over the coming months we are now able to aggressively finalize the Symphony tCGM biosensor and complete the clinical validation necessary for FDA clearance of the product. This funding enhances the Company's competitive position for Symphony in the glucose monitoring market, a $12 billion-plus annual market opportunity. We look forward to testing our commercially-ready Symphony tCGM System in a clinical trial in the near term and ultimately filing for FDA approval."

The securities issued in the financing have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States in the absence of an effective registration statement or an exemption from the registration requirements under the Securities Act.  This notice does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

About Echo TherapeuticsEc
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
5. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
6. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
7. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
8. King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY®
9. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
10. Silence Therapeutics Provides Year-end Update
11. Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... AVIV, Israel , July 22, 2014 ... a clinical-stage biopharmaceutical company focused on the development and ... of liver diseases and cholesterol gallstones, announced today that ... cleared Galmed,s Investigational New Drug, or IND, application.  Such ... its product candidate, aramchol, in the United ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
Breaking Medicine Technology:Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
(Date:7/22/2014)... heart disease, Dr. Ross Feldman says women are often in ... a men,s-only disease, however, data has shown that post-menopausal women ... and are less likely to be adequately diagnosed and treated. ... the British Journal of Clinical Pharmacology brings to ... helps to identify which women are more prone to heart ...
(Date:7/22/2014)... 2014 As reported on July 17, 2014 ... to name her favorite beauty products, “ Botox , that’s ... that “ Botox has changed my life” by halving ... preparing for her various, daily appearances. “Suddenly my eyelids ... (see: goo.gl/shmTQM). , “I think that Kelly Ripa’s response to ...
(Date:7/22/2014)... Rochelle, NY -- New guidelines on cholesterol treatment and ... double the risk of dying from atherosclerotic cardiovascular disease ... do women with a similar risk profile (based on ... The implications of this finding for when and how ... Editorial in Journal of Men,s Health , a ...
(Date:7/22/2014)... DC (PRWEB) July 22, 2014 Ticket Down ... Inter Milan tickets at Fedex Field in Landover, MD. ... to be a fan of international soccer. After the success of ... Brazil, soccer fever is alive and well. One way that fans ... for the sport is with the 2014 Guinness International Champions Cup. ...
(Date:7/22/2014)... July 22, 2014 The park is ... the Kendalltown Homeowners Association, Inc., made a ... residential community with the purchase of playground equipment from ... located in beautiful Miami Florida, and is a 475-unit ... of the surrounding landscape has created a tropical paradise ...
Breaking Medicine News(10 mins):Health News:Gene variant identified as a heart disease risk factor for women 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... proud to now serve as a presenting sponsor for the ... celebrates and supports the efforts to overcome cancer.ATLANTA, April 17 ... the science of cancer care, it,s easy to lose sight ... of the journey.Motivated by the Relay for Life events of ...
... As little as 10 minutes of exposure changes cardiovascular ... -- Cardiovascular function can be affected by as little ... other air pollutants such as wood smoke and smoke ... increasing evidence that higher levels of air pollution are ...
... study involves effort to improve chemotherapy effectiveness , , FRIDAY, April ... and testing, only a small percentage of cancer agents make ... come up with a way to weed out the duds ... marketplace. , The new model, a so-called "phase 0" ...
... April 17 In recognition of the 20th anniversary of ... global hemophilia community by pledging euro 250,000 to the World ... around the world will engage in activities to support the ... and promote support for the needs of people living with ...
... Ninety Percent of People Being Treated for Bipolar Disorder ... Depressive Symptoms (1)WASHINGTON, April 17 A ... living with bipolar disorder and 500 physicians who treat ... among people living with bipolar disorder (73%) is that ...
... making it possible to view the likely outcome of breast augmentation ... with McCormack Plastic Surgery is taking advantage of it. , ... ... asked by women considering breast surgery is typically: ‘What will I ...
Cached Medicine News:Health News:Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness 2Health News:Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness 3Health News:Secondhand Smoke Quickly Affects Blood Vessels 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 2Health News:'Phase 0' Trials Aim to Speed Cancer Drug Development 3Health News:Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia 2Health News:Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia 3Health News:Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia 4Health News:Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia 5Health News:New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1) 2Health News:New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1) 3Health News:New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1) 4Health News:New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1) 5Health News:Nevada Breast Augmentation Surgeon Gives Reno Patients a Glimpse of Likely Results with Portrait 3D Computer Imagery 2Health News:Nevada Breast Augmentation Surgeon Gives Reno Patients a Glimpse of Likely Results with Portrait 3D Computer Imagery 3
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: